An interventional study of Nestle Isocal and Nestle Boost Optimum in Colorectal Cancer, Ileus Postoperative and Flatus, sponsored by National University Hospital, Singapore. Recruiting at 1 site in Singapore. Open to participants aged 21 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-06-13.
Sponsored by National University Hospital, Singapore · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies in Colorectal Neoplasms with a site in Singapore — 13 open to participants now, 20 under way, 5 of them phase 3. Colorectal Neoplasms · Singapore.
Among the 63 studies in Colorectal Neoplasms with a site in Singapore, this one is the 30th largest by planned enrollment of the 54 interventional ones that give a count, is one of 2 that started in 2024, is one of 9 with no phase, reaches primary completion later than 4 of the 19 other live ones, and was the 57th registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →13 of the 63 studies in Colorectal Neoplasms with a site in Singapore are open now. Recruiting first, the newest first:
Singapore General Hospital · Sites in Singapore
Ages 21+
Bristol-Myers Squibb · Sites in Singapore, United States, Argentina and 22 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in Singapore, United States, Canada and 4 more countries
Ages 18+
Alentis Therapeutics AG · Sites in Singapore, United States, France and 5 more countries
Ages 18+
National University Hospital, Singapore · Sites in Singapore
Ages 21+
A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 21 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 17 · Phase 3 17
First in 1999; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 162 is above the median of 76 across 4,811 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 180 across the 54 interventional studies, 775 across the 8 observational. Of the 36 that completed or were terminated, 13 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 63 have an industry lead sponsor. The 10 most frequent:
National University Hospital, Singapore is the lead sponsor of 455 studies on the registry; 100 are open to participants now.
National University Hospital, Singapore has 9 studies filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
6 of the studies in Colorectal Neoplasms with a site in Singapore that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04912765National Cancer Centre, SingaporeNeoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC | 2026-12 |
| NCT04585750PMV Pharmaceuticals, IncThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | 2026-12-15 |
| NCT04699188Novartis PharmaceuticalsStudy of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | 2027-01-25 |
| NCT05462717Revolution Medicines, Inc.Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | 2027-03-31 |
| NCT05838768Novartis PharmaceuticalsStudy of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency. | 2027-08-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 63 studies in Colorectal Neoplasms with a site in Singapore, from their registry updates:
This tab as a report to print or save as PDF → With an account.
There is pre-existing evidence that probiotics could be useful in the improvement of ileus rates. One metaanalysis of 30 studies demonstrated a reduction in the prevalence of post-operative ileus as determined by time to flatus, time to defecation, as well as postoperative abdominal distension (PMID:37373843). More broadly in gastrointestinal surgery, a meta-analysis of 21 randomised controlled trials similarly affirmed the speedier recovery of gastrointestinal function after surgery when probiotics were administered (PMID: 35231076). In spite of these advantages, the routine use of probiotics perioperatively for colorectal cancer surgery is not performed in Singapore. We therefore seek to perform a trial to investigate whether probiotic administration perioperatively may reduce post operative ileus rates.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Control arm with no nutritional supplementation
Control arm with nutritional supplementation but without probiotics
Dietary Supplement: Nestle Isocal
Nutritional supplementation with probiotics
Dietary Supplement: Nestle Boost Optimum
Nestle Isocal
Nestle Boost Optimum
Time to bowel movement
This records the number of days from the day of surgery before the first bowel movement was experienced by the patient.
Time frame: 0 - 14 days
Time to flatus
This records the number of days from the day of surgery before the first flatus was experienced by the patient.
Time frame: 0 - 14 days
Adverse events
Any adverse events related to the intervention. This comprises predominantly gastrointestinal related complications
Time frame: From commencement of the intervention to 30 days after surgery
Infective complications
Any infective complications which may occur in the postoperative period.
Time frame: From date of surgery to 30 days after surgery
Length of hospital stay
This records the number of days following surgery before the patient is discharged.
Time frame: 0 - 14 days
Plan to share: No — Individual participant data will not be shared.
No publications or documents are linked to this record.
Start is estimated for Jul 2024; primary completion for May 2025, 10 months later.
Of 900 non-industry interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 61. This study's planned 10 months is below that.
Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National University Hospital, Singapore →